Literature DB >> 19467163

Respiratory care of the hospitalized patient with cystic fibrosis.

Thomas J Newton1.   

Abstract

Hospitalization can occur at any age for patients with cystic fibrosis (CF). The leading cause for admission is an acute worsening of signs and symptoms that can be called a pulmonary exacerbation. The reasons for admission are usually the need for intravenous antibiotics and aggressive airway clearance with good nutritional support. Respiratory therapists (RTs) play a key role in the care of CF patients in the out-patient clinics and taking care of the patients while hospitalized. Following the CF pulmonary guidelines, they administer aerosol delivery and airway clearance while also providing education to patients and families. The RT should have the skills to perform and teach all manners of airway clearance and understand the medications and delivery devices that make up a CF treatment. As CF lung disease progresses, so does the chance that these patients may develop complications such as pneumothorax and hemoptysis, which may require different strategies, especially when airway clearance is performed. The RT needs to have the skills that can take the patient from simple oxygen therapy as lung function deteriorates to the point where chronic oxygen or noninvasive ventilation is needed, or to the point where the end-stage patient waits for a lung transplant. An important aspect of the hospitalization is the interaction between the RT and the patient. To give good therapy is to be a great coach. From infection control to following proper nebulizer protocol, to consistency with airway clearance, to education, the CF RT is there for the life of the patient.

Entities:  

Mesh:

Year:  2009        PMID: 19467163     DOI: 10.4187/002013209790983232

Source DB:  PubMed          Journal:  Respir Care        ISSN: 0020-1324            Impact factor:   2.258


  4 in total

Review 1.  Cystic Fibrosis Airway Microbiome: Overturning the Old, Opening the Way for the New.

Authors:  George A O'Toole
Journal:  J Bacteriol       Date:  2018-01-24       Impact factor: 3.490

Review 2.  Pneumothorax in cystic fibrosis.

Authors:  Ioannis P Kioumis; Konstantinos Zarogoulidis; Haidong Huang; Qiang Li; Georgios Dryllis; Georgia Pitsiou; Nikolaos Machairiotis; Nikolaos Katsikogiannis; Antonis Papaiwannou; Sofia Lampaki; Konstantinos Porpodis; Bojan Zaric; Perin Branislav; Ioannis Mpoukovinas; George Lazaridis; Paul Zarogoulidis
Journal:  J Thorac Dis       Date:  2014-10       Impact factor: 2.895

3.  Real-World Outcomes Among Patients with Cystic Fibrosis Treated with Ivacaftor: 2012-2016 Experience.

Authors:  Mark Higgins; Nataliya Volkova; Kristin Moy; Bruce C Marshall; Diana Bilton
Journal:  Pulm Ther       Date:  2020-04-18

4.  Deposition of Inhaled Levofloxacin in Cystic Fibrosis Lungs Assessed by Functional Respiratory Imaging.

Authors:  Carsten Schwarz; Claudio Procaccianti; Benjamin Mignot; Hosein Sadafi; Nicolas Schwenck; Xabier Murgia; Federico Bianco
Journal:  Pharmaceutics       Date:  2021-12-01       Impact factor: 6.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.